Similar articles

• [Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].

  Leal M, Caruz A, Rey C, Lissen E. Leal M, et al. Med Clin (Barc). 1996 Nov 30;107(19):755. Med Clin (Barc). 1996. PMID: 9082095 Clinical Trial. Spanish. No abstract available.
• Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.

  [No authors listed] [No authors listed] Lancet. 1999 Jun 12;353(9169):2014-25. Lancet. 1999. PMID: 10376616
• Data and safety monitoring in the Delta trial.

  Armitage P. Armitage P. Control Clin Trials. 1999 Jun;20(3):229-41. doi: 10.1016/s0197-2456(99)00003-3. Control Clin Trials. 1999. PMID: 10357496
• [Anti-HIV therapy (1987-1994): from nothing to confusion].

  Lissen E. Lissen E. Med Clin (Barc). 1995 Apr 1;104(12):463-7. Med Clin (Barc). 1995. PMID: 7739285 Review. Spanish. No abstract available.
• Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy.

  McLeod GX, Hammer SM. McLeod GX, et al. Hosp Pract (Off Ed). 1992 Aug;27 Suppl 2:14-25. doi: 10.1080/21548331.1992.11705596. Hosp Pract (Off Ed). 1992. PMID: 1324254 Review.